In order to control busulfan pharmacokinetic variability and toxicity, a specific monitoring protocol was instituted in our bone marrow transplant BMT paediatric patients including a test dose, daily Bayesian forecasting of busulfan plasma levels, and Bayesian individualization of busulfan dosage regimens. Twenty-nine children received BMT after a busulfan-based conditioning regimen. Individual pharmacokinetic parameters were obtained following a 0.5 mg/kg test dose and were used for daily individualization of dosage regimens during the subsequent 4-day course of treatment. Doses were adjusted to reach a target mean AUC per 6 h between 4 and 6 g.h.ml
Allogeneic bone marrow transplantation (BMT) in children remains an unavoidable treatment for several haematological diseases including severe acute leukaemia, myelodysplastic syndromes, aplastic anaemia, Fanconi anaemia and congenital immunodeficiency (severe and/or combined), and also for metabolic disorders such as Hurler syndrome.
Busulfan-based conditioning regimens have been proposed as an alternative to total body irradiation before bone marrow transplantation, to avoid growth toxicity in children. 1 Busulfan has a narrow therapeutic index with major liver toxicity (veno-occlusive disease; VOD) limiting overall survival after BMT. VOD represents a major problem with a mean incidence of 20-30% and a mortality varying from 3 to 67% in different series. [2] [3] [4] [5] [6] [7] As with alkylating agents in general, therapeutic and toxic effects of busulfan have been related to the area under the plasma concentration-time curve (AUC), divided by the time between doses (6 h for busulfan). Previous studies pointed out different threshold values of AUC per 6-h dosing interval, beyond which the incidence of VOD increases. These values vary from 5 to 7 g/ml/h. [8] [9] [10] [11] [12] Only one study showed a higher threshold of 13.1 g/ml/h. 13 On the other hand, graft failure has been associated with a busulfan AUC of less than 3 to 4 g/ml/h. 8, 14 However, it is still difficult to definitively select a standard target value of AUC per 6 h of treatment, since the various studies have all been conducted under different conditions. Different methods of evaluating AUC have been employed and sometimes AUC has been calculated from plasma concentrations measured after only one dose of busulfan. This may lead to over-or under-estimation of the mean AUC observed during the 4 days of the conditioning regimen, knowing the possible intra-patient pharmacokinetic variability of busulfan. 15 Another possible problem may arise due to the measured plasma concentrations of busulfan used for calculations, depending on the mode of blood sample collection and the conveyance (rapid adsorption of busulfan on glass) and/or a lack of precision in the analytical methods used for the busulfan assay.
The narrow therapeutic index of the drug, combined with a wide inter-individual pharmacokinetic variability, makes it essentially impossible to reach a target value of AUC by using a standard dosing regimen of 1 mg/kg/6 h, especially in children. As busulfan clearance seems to be higher in young children, 10, 16 dosage adjustment using calculations based on body surface area have been proposed, 17 but these still do not allow entire control of inter-patient variation. A means of controlling it might be by an individualized dosage adjustment after determining individual pharmacokinetic model and parameter values of the drug in each patient. In order to limit the number of blood samples, Bayesian methods should be applied to estimate these individual values. 18 Consequently, as the inter-patient pharmacokinetic variability of busulfan in children does not always permit its safe or efficient use during BMT preparative regimens, we decided to apply therapeutic drug monitoring (TDM) consisting of daily monitoring of AUC by using a Bayesian estimation of busulfan clearance from an initial test dose. A prospective study included all of our patients undergoing busulfan-based BMT preparative regimens.
The purpose of this report is to present the results found in 29 children concerning the relevance of the test dose and the consequences of busulfan dosage individualization upon their clinical outcome.
Materials and methods

Patients
This prospective study enrolled all consecutive patients needing a busulfan-based conditioning regimen. Twentynine patients aged from 3 months to 18 years (mean age Ϯ s.d. = 6.9 Ϯ 5.7 years) underwent allogeneic bone marrow transplantation in our unit between January 1998 and June 2000, after a busulfan-based conditioning regimen without irradiation. All patients received an unmodified bone marrow transplant. Indications for transplantation were: storage disease (n = 9), thalassaemia major (n = 2), combined immunodeficiency or CID (n = 3), and haematological malignant diseases (ALL, n = 2; AML, n = 8; JMML, n = 1; MDS, n = 3). Table 1 summarises patient characteristics. All patients except patient 20 received alprostadil (0.125 mg/day before the age of 3 years and 0.250 mg/day above that age) and heparin 20 UI/kg/day, for 30 days after starting busulfan as prevention of veno-occlusive disease. Clonazepam (0.1 mg/kg/day) was given to prevent busulfanrelated seizures throughout the entire pre-transplant period. GVHD prophylaxis included cyclosporine for 6 months (9 months in non-malignant diseases), and short courses of methotrexate and antithymocyte globulins for unrelated donors and thalassaemia patients. Conditioning regimens were busulfan-cyclophosphamide (200 mg/kg) in 79%, busulfan-cyclophosphamide (200 mg/kg)-etoposide (60 mg/kg) in 7%, and busulfan-cyclophosphamide (200 mg/kg)-melphalan (140 mg/m 2 ) in 14% of children. All patients received intravenous immunoglobulin (0.25 g/kg/week for sibling and 0.5 g/kg/week for non-sibling donors) and were isolated in laminar air flow rooms. Busulfan was given as an individualized dose every 6 h for 4 days (a total of 16 doses). Capsules of busulfan were prepared by the pharmacy and were administered orally on an empty stomach. Capsules were swallowed by older patients or opened in a small quantity (to be sure that all the dose was consumed) of stewed apples for the youngest ones.
Busulfan assay in plasma
Plasma busulfan concentrations were determined by liquid chromatography. A new assay was developed 19 to meet the requirements of a rapid and daily dose adjustment of busulfan therapy, ie a short analysis time. Intra-day and interday coefficients of variation of the assay were less than 5%, limit of detection was 25 ng/ml and only 200 l of plasma were needed for analysis. In order to enhance the precision of the assay, particular care was used with the blood samples prior to analysis: samples were immediately placed on ice to avoid possible enzymatic degradation and were centrifuged without delay. Plasma was then immediately transferred into polypropylene tubes to avoid adsorption on to glass.
Individualization of busulfan dosage regimens
A test dose of busulfan (0.5 mg/kg) was administered orally prior to the BMT preparative regimen. Three blood samples were drawn into heparin, 1, 2.5 and 5 h after administration of busulfan. These sampling times were chosen according to the theories of optimal sampling. 20, 21 Afterwards, pharmacokinetic parameter values of a one-compartment model (first order absorption rate constant, Ka; volume of distribution related to body weight, Vs; and elimination rate constant, Kel) were estimated by using the non-linear regression modelling program included in USCPACK software. 22 The patient values of Ka, Vs and Kel were used to predict future busulfan plasma levels, and doses needed to reach a target AUC per 6 h dosing interval could be determined. Capsules containing each required dose of busulfan were prepared and quantitatively controlled (busulfan assay by HPLC) by the pharmacy.
In order to verify that our objectives of busulfan exposure were reached, AUC was monitored during the 4 days of busulfan preparation. Busulfan pharmacokinetic parameter values were evaluated on each of the 4 days using a minimal number of plasma concentration measurements: 1, 2.5 and 5 h after the first dose, 1.5 and 5 h after the fifth, ninth and 13th doses, which represented the first dose of each day of treatment. AUC was estimated by using a Bayesian modelling program included in the USCPACK software. The population pharmacokinetic parameter values were replaced by the patient values determined at the time of the test dose. In this way, intra-individual pharmacokinetic variability could be taken into account and controlled. 23 The standard deviation of the busulfan plasma concentration measurement was implemented in the Bayesian algorithm in a polynomial form: , depending on the indication for BMT, ie a lower exposure to busulfan was needed for patients with a poor marrow as observed in aplastic anaemia, and for patients with liver function weakened by previous courses of anticancer agents (patients 12, 13, 24, 25, 29) or other associated pathologies (patients 10, 14, 15) . For these patients the target value ranged arbitrarily between 3.5 and 3.8 g.h.ml −1 , based on the minimal value ensuring engraftment.
14 In practice, busulfan plasma concentrations were rapidly analysed to allow pharmacokinetic monitoring early in the day. In this way, busulfan dosage adjustment could be performed each day before the third dose on that day. In summary, doses were changed as subsequent levels were obtained over the 4 days of administration of busulfan, ie for the last 14 doses, while, the first two were determined by the test dose. In an attempt to facilitate this dosage adjustment, the pharmacy had a bank of busulfan capsules at their disposal, with dosages varying from 5 to 60 mg.
This study was approved by the Committee for Protection of Persons involved in Biomedical Research in Lyon, according to French legislation, and parents of all patients provided informed and written consent for participation.
Clinical evaluation
Predictive performances of the test dose of busulfan was assessed by comparing: (1) the mean AUC per dose interval expected resulting from simulated busulfan plasma concentrations during the 4 days by using pharmacokinetic parameter values obtained by administering the test dose (expected AUC); (2) and the mean AUC per dose interval calculated by using USCPACK and busulfan plasma concentrations measured during the 4 days of the preparative regimen (observed AUC).
All AUC values were normalised by dividing them by the individual mean dose administered over a 6-h period. The ability of the AUC expected after the test dose (expected AUC) to predict the AUC found during the busulfan regimen (observed AUC) was evaluated in two ways. First, observed and expected AUC were plotted using linear regression. Second, percentages (called percentages of 'predictivity') were calculated by using the following formula: (mean observed AUC for a dose interval (6 h)/total dose administered in mg/kg) × (total dose scheduled by the test dose/mean AUC expected for a dose interval (6 h)). The clinical benefit of busulfan dosage regimen individualisation was evaluated after matching our 29 patients (group A) with 29 control patients transplanted earlier and for whom the busulfan doses administered were those recommended by the standard SFGM or EBMT protocols (group B). Indeed, randomization seemed to be unethical to us after therapeutic drug monitoring of busulfan had became available in our hospital. Matching criteria were pre-transplant liver function, indication for BMT, the presence or absence of previous therapy including anticancer agents, VOD prophylaxis, age, and when possible, graft compatibility. Incidence of toxicity (VOD, stomatitis, pulmonary complications), graft failure (defined as evidence of no donor cells), mixed chimerism and full engraftment (defined as 100% donor chimerism) were compared in the two groups by using a Chi-squared test. Overall KaplanMeier survival, and VOD-free survival were also compared in the two groups (log-rank test). Engraftment was assessed by molecular biology on DNA extracted from medullar blood. 24 All statistical analyses were performed by using SPSS for Windows (version 9.0, SPSS, Chicago, IL, USA).
Results
Busulfan dose adjustments performed in the 29 patients are presented in Table 2 Values of mean AUC reached for a 6-h interval were in the target range (Table 3) , except for the first patients included in the study (patients 1, 16, 18, 27) . Indeed, target values were revised down after these patients, in the light of our increasing experience of the lowest values allowing engraftment.
Results of predictive performance of the test dose are presented in Figure 1 and Table 3 . Predictivity of AUC was 101.9 Ϯ 17.9%. The predictive performance of the test dose was quite complete in 52% of patients (predictivity between 90 and 110%) and correct in 83% (predictivity between 80 and 120%). A significant relationship was found between expected AUC and observed AUC, described by the following equation: observed AUC = 0.8434 × expected AUC + 0.0426 (r = 0.89, P Ͻ 0.01).
The two matched groups were comparable for their BMT indications, age, graft compatibility, and pre-transplant liver as shown in Table 4 . The incidence of VOD (all grades) in the busulfan-individualised group was significantly lower (one patient: 3.4%) than in the control group (seven patients: 24.1%) (P Ͻ 0.05). Inadvertently, the only patient in the first group who developed VOD did not receive any preventive treatment based on alprostadil and heparin. All the other patients in group A and all of those in group B received alprostadil and low-dose heparin. The mean busulfan AUC observed in this patient did not exceed 5.95 g.h.ml −1 per dose, and was not higher than that found in the majority of VOD-free patients. The occurrence of stomatitis was not significantly different in the two groups. However, severe stomatitis (grade II-IV) tended to be less frequent in group A (Table 4 ) but the differences were not ). No seizures or pulmonary toxicity related to busulfan were observed in either of the two groups.
Results for engraftment are shown in Tables 5 and 6 . Of 29 patients of group A, one died before haematological recovery, 26 achieved complete engraftment, and two had mixed chimerism. The rate of full engraftment at 3 months post transplantation was significantly higher in group A compared to group B, while it was not different at 1 year. The incidence of mixed chimerism was equivalent in the two groups. All patients in group A engrafted while 12% graft failure was observed in group B (three patients). These three patients were two Hurler and one lymphohystiocytosis transplanted with unrelated donors (one MURD, two MMURD). The mean AUC reached in patients with complete engraftment (4.74 Ϯ 1.04 g.h.ml ) was not different (Mann-Whitney, P = 0.67) from the AUC found when mixed chimerism was observed (4.47 Ϯ 0.93 g.h.ml (Figure 2 ) was 96.6% in group A, compared to 75.9 % for patients in group B (logrank test, P = 0.026). The probability of VOD was much lower (P = 0.0218) in patients with haematological malignant disease in group A (7.1%) than in group B (42.9%). This probability was not significantly different for patients with inherited disorders (0% in group A, 6.7% in group B, P Ͼ 0.05). Overall survival was 82.8% in group A vs 65.5% in group B, with a median follow-up lower in group A (1.6 years vs 2.0 in group B). The primary cause of early death was VOD. All other deaths were due to infections (mainly cytomegalovirus or aspergillus pneumonia and disseminated adenovirus infection) or acute GVHD.
Discussion
To our knowledge, this study is the first applying Bayesian pharmacokinetic monitoring over the 4 days of busulfan treatment using sparse clinical data, ie a limited number of blood samples. Most of the previous pharmacokinetic studies were confined to estimating AUC only after the first dose or after the first and the thirteenth doses.
14,25-27 Our study design allowed us to estimate AUC after the first dose on each of the 4 days of busulfan treatment. This was possible by using Bayesian methods allowing the estimation of individual pharmacokinetic parameter values from only one-to three-drug plasma levels. This method allows reliable calculation of AUC, based on busulfan plasma concentrations measured using a precise HPLC assay. Our primary goal was to evaluate the relevance of a test dose of busulfan. Our results showed that the test dose was useful in predicting individual pharmacokinetics during the pre-transplant conditioning regimen. However, although the test dose predicting performance was good for the majority of patients, some patients had different pharmacokinetic behaviour at the time of the pre-transplant conditioning regimen. Because of such patients, the test dose does not exempt one from performing therapeutic drug monitoring during the 4 days of conditioning with busulfan. The test dose allows initial dosage individualization of busulfan although further monitoring and dose adjustments are subsequently needed to control possible intra-patient pharmacokinetic variability. 28 Most patients received a lower total dose of busulfan than those usually recommended. However, no graft rejection or graft failure was observed, and the rate of full engraftment was higher than in patients who received conventional dosages. VOD incidence was particularly low. This might be because constant busulfan exposure was ensured during the 4 days, because of the results of daily drug plasma level monitoring, and based on the dose adjustment performed the day before. Indeed, the only patient with VOD experienced great variations of his daily busulfan AUC (data not shown). This patient had also received high doses of intravenous immunoglobulin, which has been recently shown to enhance the risk of VOD. 29 Although 749  Table 4 Comparison of group A and group B patient characteristics doses were low, the occurrence of mixed chimerism was not higher. We could not explain why some patients in both groups became mixed chimeras at 1 year. However, all of their grafts remained functional with no effect on clinical status. The incidence of relapse was not studied since the lack of influence of mixed chimerism on risk of relapse in ALL or AML has been shown. 30 Moreover, retrospective analysis of some patients may still be insufficient to draw any conclusions.
There was no clear relation between AUC values and occurrence of stomatitis, which can also result with other conditioning agents such as etoposide or cyclophosphamide. This can also be applied to the incidence of mixed chimerism. However, the values of the observed AUC were all in a narrow range. Moreover, this study confirms the target values of busulfan exposure or AUC, which should probably be between 3.5 and 5 g.h.ml Individualized busulfan dosages improved early posttransplantation outcome, as shown by the lower probability of developing VOD and the 90-day survival. Infectionrelated mortality remains a concern.
In conclusion, this study shows that clinical outcome of paediatric bone marrow recipients receiving a bu-containing conditioning regimen can be improved by giving a busulfan dosage adapted to individual pharmacokinetic parameter values, to achieve desired target goals more precisely. Daily drug plasma monitoring and Bayesian feedback control of the dosage regimen nevertheless still appears essential to ensure that busulfan exposure does not vary excessively from day to day, due to intra-patient pharmacokinetic variability. This daily evaluation is made easier by using population pharmacokinetic models and a Bayesian fitting algorithm since relatively few blood samples are needed. Table 6 Results of chimerism assessment in the two groups 
Patient number
